{
    "organizations": [],
    "uuid": "fdbc425a2ccaff34a1f9091acd961a81c11f634b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-argenx-to-present-complete-data-fr/brief-argenx-to-present-complete-data-from-phase-2-clinical-trial-of-efgartigimod-idUSFWN1RG02S",
    "ord_in_thread": 0,
    "title": "BRIEF-Argenx ‍To Present Complete Data From Phase 2 Clinical Trial Of Efgartigimod",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 3 (Reuters) - ARGENX NV:\n* ‍TO PRESENT COMPLETE DATA FROM PHASE 2 CLINICAL TRIAL OF EFGARTIGIMOD (ARGX-113) IN MYASTHENIA GRAVIS​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-03T13:11:00.000+03:00",
    "crawled": "2018-04-04T12:21:49.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "argenx",
        "nv",
        "present",
        "complete",
        "data",
        "phase",
        "clinical",
        "trial",
        "efgartigimod",
        "myasthenia",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}